Summary
EudraCT Number: 2005-004866-17
Sponsor's Protocol Code Number: 01/2005
National Competent Authority: Germany - BfArM 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2005-11-22
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004866-17/DE/

A. Protocol Information
A.1 Member State Concerned: Germany - BfArM
A.2 EudraCT number: 2005-004866-17
A.3 Full title of the trial: An Open-label, single arm Phase II Trial of Photodynamic Therapy using Foscan for non-curatively-resectable bile duct carcinoma
A.3.2 Name or abbreviated title of the trial where available: Foscan-PDT-protocol for BDC
A.4.1 Sponsor's protocol code number: 01/2005
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: Dept Medicine I, Paracelsus Med. Univ.	Landeskrankenanstalten Salzburg / SALK
B.1.3.4	Country: Austria
B.3.1 and B.3.2	Status of the sponsor: Non-Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Solution for injection
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Temoporfin
D.3.9.1 CAS number: 122341-38-2
D.3.10 Strength
D.3.10.1 Concentration unit: mg/ml milligram(s)/millilitre
D.3.10.3 Concentration number: 4 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: Information not present in EudraCT
D.3.11.8 Extractive medicinal product: Information not present in EudraCT
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Nonresectable hilar or extrahepatic bile duct carcinoma in clinical stage MO ( without liver or peritoneal metastases according to clinical or surgical staging)
MedDRA Classification
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: To assess Foscan (temoporfiin) photodynamic therapy tumorocidal penetration greater than 8mm. To assess efficacy and safety of Foscan (temoporfiin) photodynamic therapy in the treatment of locally advanced hilar or extrahepatic bile duct carcinoma without distant metastases.
E.2.2 Secondary objectives of the trial: - Progression-free survival time, overall survival time
- Rate of systemic response (RECIST criteria / EORTC)(37).
- Toxicity using WHO criteria and criteria for local toxicity in the biliary system
E.2.3 Trial contains a sub-study: Information not present in EudraCT
E.3 Principal inclusion criteria: * bile duct carcinoma proven by histology in advanced or non-operable stage or tumor extension:
a) Bismuth type 111 or IV ( not resectable with RO-margins ),
b) Bismuth type I or II, if resective surgery is contraindicated for old age
or poor surgical risk of patient
* sufficient general condition to undergo PDT (Karnofsky status 2 30%)
* age> 19 years
* access to common bile duct (either via endoscopy after sphincterotomy or percutaneously after transhepatic drainage),
* informed written consent for PDT.
E.4 Principal exclusion criteria: * porphyria or other diseases exacerbated by light
* known intolerance or allergies to porphyrin derivatives
* a planned surgical procedure within the next 30 days
* coexisting ophthalmic disease likely to require slit lamp examination within the next 30 days
* impaired kidney or liver function (creatinine > 2.5x elevated, INR > 2.2 on vitamin K),
* leukopenia ( WBC < 2000/cmm ) or thrombopenia ( < 50000/cmm ),
* cytotoxic chemotherapy within the past 4 weeks.
* pregnancy ( and safe contraception for 6 months after PDT )
* accompaning/complicating disease with very poor prognosis (expected survival < 6 weeks),
* proven advanced peritoneal carcinomatosis (PET scan imaging, ascites positive for tumor cells)
E.5 End points
E.5.1 Primary end point(s): Rate of local response and depth of tumoricidal tissue penetration of Foscan-PDT
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: Information not present in EudraCT
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): Yes
E.7.3 Therapeutic confirmatory (Phase III): No
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: No
E.8.1.1 Randomised: No
E.8.1.2 Open: Information not present in EudraCT
E.8.1.3 Single blind: Information not present in EudraCT
E.8.1.4 Double blind: Information not present in EudraCT
E.8.1.5 Parallel group: Information not present in EudraCT
E.8.1.6 Cross over: Information not present in EudraCT
E.8.1.7 Other: Information not present in EudraCT
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: No
E.8.2.3 Other: No
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.5 The trial involves multiple Member States: Yes
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: Information not present in EudraCT
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: 
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 2
E.8.9.1 In the Member State concerned months: 0
E.8.9.1 In the Member State concerned days: 

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Information not present in EudraCT
F.3.3.1 Women of childbearing potential not using contraception  
(For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and
did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether
or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the
database on 2005-11-22) : Yes
F.3.3.2 Women of child-bearing potential using contraception: Information not present in EudraCT
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 35
F.4.2.2 In the whole clinical trial: 35

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2006-09-05
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2007-04-03

P. End of Trial
P. End of Trial Status: Completed
P. Date of the global end of the trial: 2012-12-31

